Showing 741-750 of 1100 results for "".
- Dr. Rafael Sierra is Cynosure's Newest R&D Advisorhttps://practicaldermatology.com/news/dr-rafael-sierra-is-cynosures-newest-rd-advisor/2460533/Rafael Sierra, PhD is back at Cynosure. The former Chief Technology Officer is now an R&D Advisor. "Dr. Sierra's passion for the science behind medical aesthetics and inherent knowledge of its clinical application are unparalleled," says Todd
- Amytrx Therapeutics Comes Out of the Gate Strong with Lead Program AMTX-100, Clinical Development Planshttps://practicaldermatology.com/news/amytrx-therapeutics-comes-out-of-the-gate-strong-with-lead-program-amtx-100-clinical-development-plans/2460531/Amytrx Therapeutics, Inc. is on the move. Founded in 2014, Nashville-based Amytrx is developing novel therapies for inflammatory diseases with lead program AMTX-100 currently in clinical development for dermatologic indications. AMTX-100 is a new anti-inflammatory therape
- Laseroptek Introduces Pallas UVB Laser in UShttps://practicaldermatology.com/news/laseroptek-introduces-pallas-uvb-laser-in-us/2460499/South Korea-based Laseroptek Co., Ltd. is launching the Pallas Solid-State 311nm UVB laser for the treatment of vitiligo, psoriasis, atopic dermatitis and leukoderma in the United States. Pallas allows the choice of either 308 or 311 nanomet
- Verrica Enters Agreement with Lytix for Oncolytic Peptide for Dermatologyhttps://practicaldermatology.com/news/verrica-enters-agreement-with-lytix-for-oncolytic-peptide-for-dermatology/2460498/Verrica Pharmaceuticals Inc. has entered into an exclusive worldwide license agreement with Lytix Biopharma AS to develop and commercialize LTX-315 for dermatologic oncology indications. Verrica intends to focus initially on basal cell and squamous cell carcinoma
- This Is Why Sarecycline Is So Effective Against Acnehttps://practicaldermatology.com/news/this-is-why-sarecycline-is-so-effective-against-acne/2460488/Researchers at Yale and the University of Illinois-Chicago have discovered how Sarecycline’s unique chemical structure makes it so effective against acne. Unlike other tetracycline drugs, sarecycline binds to messenger RNA (mRNA) in bacterial ribosomes. Sarecycline and other
- Rihanna Introduces Fenty Skinhttps://practicaldermatology.com/news/rihanna-introduces-fenty-skin/2460487/Rihanna, in partnership with Kendo Brands, is rolling out Fenty Skin. After years of feeling overwhelmed by all the skincare choices and a bad experience with a product that discolored her skin as a teen, Rihanna dreamed of creating a line that was easy and effective. Now, she'
- Win for MC2 Therapeutics: Wynzora Cream Approved for Adults with Psoriasishttps://practicaldermatology.com/news/win-for-mc2-therapeutics-wynzora-cream-approved-for-adults-with-psoriasis/2460476/FDA has approved Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) from MC2 Therapeutics for once-daily topical treatment of plaque psoriasis in adults 18 years of age or older. The approval is based on results of the US Phase 3 clinical trial&nbs
- Pulse Biosciences, Inc.’s Nano-Pulse Stimulation Technology Produces Favorable Results for Warts and Allhttps://practicaldermatology.com/news/pulse-biosciences-incs-nano-pulse-stimulation-technology-produces-favorable-results-for-warts-and-all/2460457/Three studies show positive results for Pulse Biosciences, Inc.’s investigational use of Nano-Pulse Stimulation non-thermal energy in nodular basal cell carcinoma (BCC), sebaceous hyperplasia (SH) lesions and cutaneous non-genital warts. In addition, pre-clinical observations of t
- AOBiome Initiates Phase 2b Clinical Trial of B244 in Adults with ADhttps://practicaldermatology.com/news/aobiome-initiates-phase-2b-clinical-trial-of-b244-in-adults-with-ad/2460450/AOBiome Therapeutics, Inc. is initiating a Phase 2b clinical trial of its lead product candidate, B244, in pruritus associated with atopic dermatitis. B244 is a first-in-class, topical formulation of beneficial ammonia oxidizing bacteria that is delivered as a spray twice daily for 28 d
- Ortho Dermatologics Launches Arazlo Lotion in the UShttps://practicaldermatology.com/news/ortho-dermatologics-launches-arazlo-lotion-in-the-us/2460447/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics launched Arazlo (tazarotene) Lotion, 0.045%. Now available commercially to health care professionals in the US, it was FDA approved in December 2019 as the first tazaroten